16 research outputs found
ΠΠΠ‘Π£ΠΠΠ Π‘Π’ΠΠΠΠΠΠ― ΠΠΠΠ ΠΠΠΠ’ΠΠ¦ΠΠ― ΠΠΠ ΠΠΠΠΠΠ’ΠΠΠ¬ΠΠ«Π₯ ΠΠ ΠΠΠ ΠΠΠ Π€ΠΠΠ£ Β«Π€ΠΠ¦Π’ΠΠ ΠΠΠΠΠ ΠΠΠΠΠΠΠΠΠ Π.Π. Π¨Π£ΠΠΠΠΠΠΒ» ΠΠΠΠΠΠ ΠΠΠ Π ΠΠ‘Π‘ΠΠ
State accreditation of the educational programs in the V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs.ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½Π°Ρ Π°ΠΊΠΊΡΠ΅Π΄ΠΈΡΠ°ΡΠΈΡ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ Π€ΠΠΠ£ Β«Π€ΠΠ¦Π’ΠΠ ΠΈΠΌΠ΅Π½ΠΈ Π°ΠΊΠ°Π΄Π΅ΠΌΠΈΠΊΠ° Π.Π. Π¨ΡΠΌΠ°ΠΊΠΎΠ²Π°Β» ΠΠΈΠ½Π·Π΄ΡΠ°Π²Π° Π ΠΎΡΡΠΈΠΈ
Π‘Π²ΡΠ·Ρ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ
Objective: to analyze the correlation between the expression levels of microRNA-101, microRNA-142, microRNA-27, microRNA-339, and microRNA-424 and the plasma concentrations of biomarkers that are potentially significant for the diagnosis of post-transplant complications in heart recipients. Materials and methods. The study enrolled 72 heart recipients, among whom were 56 men (77.8%). The average age of recipients was 48.6 Β± 10.9 (16 to 70) years. There were 38 patients with severe chronic heart failure, among whom were 29 men (76.3%). Patientsβ mean age was 48.8 Β± 9.9 (26 to 70) years. The control group consisted of 12 healthy individuals who did not differ significantly by sex and age. microRNA expression levels in blood plasma were measured via quantitative polymerase chain reaction. Plasma concentrations of VEGF-A, PLGF, MCP-1, and sCD40L were determined using a multiplex method. ST2 and Galectin-3 concentrations were measured via enzyme-linked immunosorbent assay. Results. Patients with end-stage chronic heart failure were found to have significantly higher expression levels of microRNA-27, microRNA-339 and microRNA-424 in blood plasma compared with the healthy individuals. In potential heart recipients, the expression le vels of microRNA-339 and microRNA-424 correlated with serum galectin-3 concentrations, microRNA-101 expression levels correlated with PLGF-1 concentrations, while microRNA-27 expression levels correlated with plasma MCP-1 concentrations. In the early post-transplant period, the expression levels of microRNA-101, microRNA-339, and microRNA-424 in heart recipients were significantly lower than in patients with severe chronic heart failure. In the early post-transplant period (one year or more after transplantation), microRNA-101 and microRNA-27 expression levels were significantly higher than in heart recipients. A year or more after transplantation, the following correlations were found in heart recipients: microRNA-142 expression level correlated with serum levels of galectin-3 (p = 0.05), microRNA-27 and microRNA-424 expression levels correlated with ST2 concentrations (p = 0.02), microRNA-27 expression level correlated with PLGF-1 concentrations (p = 0.02), while microRNA-101 expression level correlated with serum levels of PAPP-A (p = 0.05). Conclusion. In heart recipients, the expression levels of microRNA-142, microRNA-27, microRNA-424, and microRNA-101 correlate with the concentration levels of biomarkers of fibrosis (Galectin-3), rejection (ST2), neoangiogenesis (PLGF), and tissue destruction (PAPP-A). A comprehensive analysis of pre- and post-translational markers may open up new perspectives in diagnosis, assessment of the risks of post-transplant complications, and in understanding the processes leading to their development.Π¦Π΅Π»Ρ: Π°Π½Π°Π»ΠΈΠ· ΡΠ²ΡΠ·ΠΈ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-142, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-339 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², ΡΡΠ°ΡΡΠ²ΡΡΡΠΈΡ
Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ Π·Π½Π°ΡΠΈΠΌΡΡ
Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 72 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ° ΡΠ΅ΡΠ΄ΡΠ°, ΡΡΠ΅Π΄ΠΈ Π½ΠΈΡ
ΠΌΡΠΆΡΠΈΠ½ β 56 (77,8%), ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 48,6 Β± 10,9 (ΠΎΡ 16 Π΄ΠΎ 70) Π³ΠΎΠ΄Π°, ΠΈ 38 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ, ΡΡΠ΅Π΄ΠΈ Π½ΠΈΡ
ΠΌΡΠΆΡΠΈΠ½ β 29 (76,3%), ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 48,8 Β± 9,9 (ΠΎΡ 26 Π΄ΠΎ 70) Π³ΠΎΠ΄Π°. ΠΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 12 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ, Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΠΈΡ
ΡΡ ΠΏΠΎ ΠΏΠΎΠ»Ρ ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΡ. Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ VEGF-A, PLGF, MCP-1 ΠΈ sCD40L Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π°. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ST2 ΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-339 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ Π»ΠΈΡΠ°ΠΌΠΈ. Π£ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-339, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π» Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3, ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 β Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ PLGF-1, ΡΡΠΎΠ²Π΅Π½Ρ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 β Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ MCP-1. Π ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-339 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 Π±ΡΠ» Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ. Π§Π΅ΡΠ΅Π· Π³ΠΎΠ΄ ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 Π±ΡΠ» Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Π² ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ. Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° ΡΠΏΡΡΡΡ Π³ΠΎΠ΄ ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ ΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-142 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 (p = 0,05), ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ ST2 (p = 0,02), ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ PLGF-1 (p = 0,02), ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ PAPP-A (p = 0,05). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Π²Π΅Π»ΠΈΡΠΈΠ½Π° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-142, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΡΠ²ΡΠ·Π°Π½Π° Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΡΠΈΠ±ΡΠΎΠ·Π° (Π³Π°Π»Π΅ΠΊΡΠΈΠ½-3), ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ (ST2), Π½Π΅ΠΎΠ°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π° (PLGF) ΠΈ Π΄Π΅ΡΡΡΡΠΊΡΠΈΠΈ ΡΠΊΠ°Π½Π΅ΠΉ (PAPP-A). ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π΄ΠΎ- ΠΈ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠ»ΡΡΠΈΠΎΠ½Π½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΌΠΎΠΆΠ΅Ρ ΠΎΡΠΊΡΡΡΡ Π½ΠΎΠ²ΡΠ΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΊΠ°ΠΊ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅, ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΈΡΠΊΠΎΠ² ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, ΡΠ°ΠΊ ΠΈ Π² ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ², Π²Π΅Π΄ΡΡΠΈΡ
ΠΊ ΠΈΡ
ΡΠ°Π·Π²ΠΈΡΠΈΡ
ST2 ΠΠ Π ΠΠ’Π’ΠΠ ΠΠΠΠΠ Π’Π ΠΠΠ‘ΠΠΠΠΠ’ΠΠ ΠΠΠΠΠΠΠΠ Π‘ΠΠ ΠΠ¦Π
This review summarizes the current literature devoted to the analysis of prognostic role of ST2 biomarker in rejection of the transplanted heart. ST2 is one of the most promising diagnostic markers of the development and severity of heart failure as well as the mortality risk in patients with cardiovascular diseases. ST2 is expressed in cardiomyocytes in response to a variety of pathological processes and mechanical damage to the heart, which allows diagnosing cardiovascular diseases before clinical manifestations. Presumably, measuring the level of ST2 in heart transplant may have diagnostic and prognostic value in the assessment of graft and risk of rejection. Currently, accumulated clinical data on the role of given biomarker in heart transplantation are not enough, and further research on the relation of ST2 levels with different clinical and laboratory parameters in heart recipients is necessary.Β ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½ Π°Π½Π°Π»ΠΈΠ·Ρ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΈΜ ΡΠΎΠ»ΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° ST2 ΠΏΡΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ°. ST2 ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΈΜ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΈΡΠΊΠ° ΡΠΌΠ΅ΡΡΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ. ST2 ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΠ΅ΡΡΡ Π² ΠΊΠ°ΡΠ΄ΠΈΠΎΠΌΠΈΠΎΡΠΈΡΠ°Ρ
Π² ΠΎΡΠ²Π΅Ρ Π½Π° ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Π² ΡΠ΅ΡΠ΄ΡΠ΅, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°ΡΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π΅ΡΠ΅ Π΄ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΈΜ. ΠΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ST2 ΠΏΡΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ° ΠΌΠΎΠΆΠ΅Ρ ΠΈΠΌΠ΅ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄Π°Π½Π½ΡΡ
ΠΎ ΡΠΎΠ»ΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΏΡΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ° Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΎ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ, ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡ Π΄Π°Π»ΡΠ½Π΅ΠΈΜΡΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΡΠ·ΠΈ ΡΡΠΎΠ²Π½Ρ ST2 Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°.
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΎΠ»ΠΎΠ³ΠΈΡ: ΠΏΠ°ΠΌΡΡΠ½ΡΠ΅ Π΄Π°ΡΡ ΠΈ Π½ΠΎΠ²Π΅ΠΉΡΠΈΠ΅ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ (Π’ΡΠ΅ΡΠΈΠΉ Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ ΠΊΠΎΠ½Π³ΡΠ΅ΡΡ Β«Π’ΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ ΠΈ Π΄ΠΎΠ½ΠΎΡΡΡΠ²ΠΎ ΠΎΡΠ³Π°Π½ΠΎΠ²Β»)
.2β4 ΠΎΠΊΡΡΠ±ΡΡ 2017 Π³ΠΎΠ΄Π° Π² ΠΠΎΡΠΊΠ²Π΅, Π² ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΌ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΎΠΌ ΡΠ΅Π½ΡΡΠ΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΈΠΌΠ΅Π½ΠΈ Π°ΠΊΠ°Π΄Π΅ΠΌΠΈΠΊΠ° Π.Π. Π¨ΡΠΌΠ°ΠΊΠΎΠ²Π°, ΡΠΎΡΡΠΎΡΠ»ΡΡ Π’ΡΠ΅ΡΠΈΠΉ Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ ΠΊΠΎΠ½Π³ΡΠ΅ΡΡ Β«Π’ΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ ΠΈ Π΄ΠΎΠ½ΠΎΡΡΡΠ²ΠΎ ΠΎΡΠ³Π°Π½ΠΎΠ²Β»
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°β3 ΠΏΡΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ°
Objective: to determine the diagnostic value of galectin-3 in transplant recipients with myocardial fibrosis and acute heart transplant rejection, verified by endomyocardial biopsy. Materials and methods. The study included 124 patients with end-stage heart failure. Their ages ranged from 16 to 71 (average 48 Β± 12) years, of which 106 (85%) were men and 18 (15%) were women. From 2013 to 2016, these patients underwent a heart transplant procedure at the Shumakov National Medical Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation. Analysis of endomyocardial biopsy specimens was used to verify acute cellular, humoral rejection and myocardial fibrosis of the heart transplant. Severity and nature of fibrosis was evaluated using a qualitative imaging technique. Galectin-3 concentration was measured by enzyme immunoassay using Human Galectin-3 Platinum ELISA reagent kits (Bender MedSystems GmbH, Vienna, Austria). Results. In the long-term post-transplantation period, in comparison with the early post-transplantation period, the number of verified graft myocardial fibrosis increased by 88% in recipients who had acute rejection crises and by 37% in recipients who had no rejection crises. Graft myocardial fibrosis was detected more often in recipients who had acute humoral rejection than in those who had acute cell rejection (92% vs 75% of cases, respectively). Plasma galectin-3 levels in recipients with graft myocardial fibrosis was higher than in recipients without it (p = 0.05 1 year and p = 0.01 1β5 years after heart transplantation). In recipients who had acute rejection crises, the risk of developing graft myocardial fibrosis was 1.64 (RR = 1.64 Β± 0.1 [95% CI 1.1β2.2]). Conclusion. Galectin-3 is a biomarker for myocardial fibrosis in acute heart transplant rejection.Π¦Π΅Π»Ρ: ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°β3 Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈ ΠΎΡΡΡΡΠΌ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°, Π²Π΅ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΠΏΡΠΈ ΡΠ½Π΄ΠΎΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠΏΡΠΈΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 124 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ, Π²ΠΎΠ·ΡΠ°ΡΡ β ΠΎΡ 16 Π΄ΠΎ 71 (Π² ΡΡΠ΅Π΄Π½Π΅ΠΌ 48 Β± 12) Π³ΠΎΠ΄Π°, ΠΈΠ· Π½ΠΈΡ
106 (85%) ΠΌΡΠΆΡΠΈΠ½ ΠΈ 18 (15%) ΠΆΠ΅Π½ΡΠΈΠ½, ΠΊΠΎΡΠΎΡΡΠΌ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 2013-Π³ΠΎ ΠΏΠΎ 2016 Π³ΠΎΠ΄ Π² Π€ΠΠΠ£ Β«ΠΠΠΠ¦ Π’ΠΠ ΠΈΠΌ. Π°ΠΊ. Π.Π. Π¨ΡΠΌΠ°ΠΊΠΎΠ²Π°Β» ΠΠΈΠ½Π·Π΄ΡΠ°Π²Π° Π ΠΎΡΡΠΈΠΈ Π±ΡΠ»Π° Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ ΡΠ΅ΡΠ΄ΡΠ°. ΠΠ΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ, Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΡΠ½Π΄ΠΎΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΡΡ
Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ²; Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡ ΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°β3 ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π½Π°Π±ΠΎΡΠΎΠ² ΡΠ΅Π°Π³Π΅Π½ΡΠΎΠ² Human Galectinβ3 Platinum ELISA (Bender MedSystems GmbH, ΠΠ΅Π½Π°, ΠΠ²ΡΡΡΠΈΡ). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΡΠ°Π½Π½ΠΈΠΌ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΎΠΌ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅ΡΡΡ ΡΠΈΡΠ»ΠΎ Π²Π΅ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°: Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΊΡΠΈΠ·Ρ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ β Π½Π° 88%, Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· ΠΊΡΠΈΠ·ΠΎΠ² ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ β Π½Π° 37%. Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΎΡΡΡΠΎΠ΅ Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅, ΡΠΈΠ±ΡΠΎΠ· ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Π²ΡΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΡΠ΅, ΡΠ΅ΠΌ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΎΡΡΡΠΎΠ΅ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ΅ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ (Π² 92 ΠΈ 75% ΡΠ»ΡΡΠ°Π΅Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). Π£ΡΠΎΠ²Π΅Π½Ρ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°β3 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· ΡΠ°ΠΊΠΎΠ²ΠΎΠ³ΠΎ (p = 0,05 ΡΠΏΡΡΡΡ Π³ΠΎΠ΄ ΠΈ p = 0,01 ΡΠΏΡΡΡΡ 1β5 Π»Π΅Ρ ΠΏΠΎΡΠ»Π΅ Π’Π‘). Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΊΡΠΈΠ·Ρ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ, ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΡΠΎΡΡΠ°Π²ΠΈΠ» 1,64 (RR = 1,64 Β± 0,1 [95% ΠΠ 1,1β2,2]). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°Π»Π΅ΠΊΡΠΈΠ½β3 ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΊΡΠΈΠ·Ρ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ
ΠΠΠΠΠΠΠ‘Π’ΠΠ§ΠΠ‘ΠΠΠ ΠΠΠΠ§ΠΠΠΠ Π’Π ΠΠΠΠΠ¦ΠΠ’ΠΠ ΠΠΠΠ Π€ΠΠΠ’ΠΠ Π Π ΠΠ‘Π’Π PDGF-BB Π ST2 ΠΠ Π ΠΠ’Π’ΠΠ ΠΠΠΠΠ Π’Π ΠΠΠ‘ΠΠΠΠΠ’ΠΠ ΠΠΠΠΠΠΠΠ Π‘ΠΠ ΠΠ¦Π
Aim: to determine the association between plasma concentrations of biomarkers (sCD40L, PDGF-BB, PlGF-1,Β ST2) with histochemical and immunohistochemical signs of heart rejection.Materials and methods. The studyΒ included 98 heart recipients aged from 12 to 69 (mean age 43 Β± 14) years, of which 78 men. In 68 patients dilatedΒ cardiomyopathy was diagnosed, 30 recipients were diagnosed with coronary heart disease. The concentrationsΒ of placental growth factor (PlGF-1), platelet-derived growth factor (PDGF-BB), soluble CD40 ligand (sCD40L)Β were measured using xMAP technology. The concentrations of ST2 cardiac biomarker were measured byΒ ELISA.Results. No correlation was found between the levels of biomarkers (sCD40L, PDGF-BB, PlGF-1, ST2)Β and gender, age and diagnosis. The rejection was diagnosed via biopsy in 49 biopsies taken from 37 recipients.Β 1A rejection was found in 25 patients (34 biopsies), 1B rejection was identifi ed in 2 patients (3 biopsies), 3AΒ rejection was diagnosed in 4 patients. Immunohistochemical signs of humoral rejection were identifi ed in 3 patients.Β The combination of acute cellular and humoral rejection was found in 4 patients (5 biopsies). The PDGFBBΒ level was measured at the same day as the biopsy was taken, and it was shown to be signifi cantly higher inΒ patients with rejection (p = 0.02). Rejection frequency was signifi cantly higher in patients with high PDGF-BBΒ level (β₯2473.7 pg/ml, RR = 1.64 Β± 0.23; 95% CI [1.03β2.61]). Rejection frequency increased to 2.11 Β± 0.34Β [95% CI [1.08β4.11]] in recipients with ST2 and PDGF-BB concentration higher than the median value. TheΒ highest predictive value for heart rejection can be reached by a panel of three biomarkers: sCD40L, PlGF-1 andΒ ST2 (RR = 2.51 Β± 0.38; 95% CI [1.18β5.3]).Conclusion. PDGF-BB has moderate predictive value for heartΒ rejection. The highest predictive value for heart rejection was reached by a panel of three biomarkers: sCD40L,Β PlGF-1 and ST2.Π¦Π΅Π»Ρ: ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ²ΡΠ·Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² sCD40L, PDGF-BB, PlGF-1, ST2 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡΡ Π³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ²Β ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 98 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²Β Ρ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ΅ΡΠ΄ΡΠ΅ΠΌ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 12 Π΄ΠΎ 69 (43 Β± 14) Π»Π΅Ρ, ΠΈΠ· Π½ΠΈΡ
78 ΠΌΡΠΆΡΠΈΠ½. Π£ 68 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π΄ΠΎ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ° Π±ΡΠ»Π° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π° Π΄ΠΈΠ»Π°ΡΠ°ΡΠΈΠΎΠ½Π½Π°Ρ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°ΡΠΈΡ, Ρ 30 β ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ ΡΠ΅ΡΠ΄ΡΠ°. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° (PlGF-1), ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ²Β (PDGF-BB), ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΠΉ ΡΠΎΡΠΌΡ Π»ΠΈΠ³Π°Π½Π΄Π° CD40 (sCD40L) ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉΒ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ; ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° ST2 β Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΠΊΠ°ΠΆΠ΄ΠΎΠ³ΠΎ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° Π½Π΅ Π·Π°Π²ΠΈΡΠ΅Π»Π° ΠΎΡ ΠΏΠΎΠ»Π°, Π²ΠΎΠ·ΡΠ°ΡΡΠ° ΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° Π΄ΠΎ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ. Π£ 37 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (ΠΏΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ 49 Π±ΠΈΠΎΠΏΡΠΈΠΉ) Π±ΡΠ»ΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ.Β ΠΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ β Ρ 30 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² (Π² 41 Π±ΠΈΠΎΠΏΡΠ°ΡΠ΅): 1Π β ΡΒ 25 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (Π² 34 Π±ΠΈΠΎΠΏΡΠ°ΡΠ°Ρ
), 1Π β Ρ Π΄Π²ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (Π² ΡΡΠ΅Ρ
Π±ΠΈΠΎΠΏΡΠ°ΡΠ°Ρ
), 3Π β Ρ ΡΠ΅ΡΡΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².Β ΠΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ Π°Π½ΡΠΈΡΠ΅Π»ΠΎΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ Π²ΡΡΠ²Π»Π΅Π½Ρ Ρ ΡΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².Β Π‘ΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈ Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ Ρ ΡΠ΅ΡΡΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (Π² ΠΏΡΡΠΈΒ Π±ΠΈΠΎΠΏΡΠ°ΡΠ°Ρ
). ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ PDGF-BB, ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½Π½Π°Ρ Π² Π΄Π΅Π½Ρ ΡΠ½Π΄ΠΎΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠΏΡΠΈΠΈ, Π±ΡΠ»Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΒ Π²ΡΡΠ΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ΠΌ (p = 0,02). Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ PDGF-BB Π²ΡΡΠ΅ ΠΌΠ΅Π΄ΠΈΠ°Π½ΡΒ (2473,7 ΠΏΠ³/ΠΌΠ») ΡΠΈΡΠΊ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ Π±ΡΠ» Π² 1,64 ΡΠ°Π·Π° Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ Π½ΠΈΠΆΠ΅ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ. Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ ΠΈ ST2, ΠΈ PDGF-BB, ΠΏΡΠ΅Π²ΡΡΠ°ΡΡΠ΅ΠΉ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ, ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΊΒ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π» Π΄ΠΎ 2,11 Β± 0,34 [95% ΠΠ 1,08β4,11]. ΠΠ°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡΒ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΎΠ±Π»Π°Π΄Π°Π»Π° ΠΏΠ°Π½Π΅Π»Ρ ΠΈΠ· ΡΡΠ΅Ρ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² (sCD40L, PlGF-1, ST2):Β RR = 2,51 Β± 0,38 [95% ΠΠ 1,18β5,3].ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. PDGF-BB ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ ΡΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠΉ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ°. ΠΠ°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ ΠΏΠ°Π½Π΅Π»Ρ ΠΈΠ· ΡΡΠ΅Ρ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ²: sCD40L, PlGF-1, ST2
ΠΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠΎΡΠΊΠΈ
Fibrosis is one of the causes of kidney allograft loss, especially late after transplantation (up to 65% incidence after 2 years). The purpose of this literature review is to analyze studies examining noninvasive monitoring techniques for renal graft fibrosis.Π€ΠΈΠ±ΡΠΎΠ· ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· ΠΏΡΠΈΡΠΈΠ½ ΠΏΠΎΡΠ΅ΡΠΈ Π°Π»Π»ΠΎΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΏΠΎΡΠΊΠΈ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ Π² ΠΏΠΎΠ·Π΄Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ (ΡΠ°ΡΡΠΎΡΠ° Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ β Π΄ΠΎ 65% ΡΠ΅ΡΠ΅Π· 2 Π³ΠΎΠ΄Π°). Π¦Π΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΎΠ±Π·ΠΎΡΠ° Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°Π½Π°Π»ΠΈΠ· ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΈΠ·ΡΡΠ°ΡΡΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄Ρ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΠΎΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°
Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΠΏΠ°Π½Π΅Π»Π΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Π²Β ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ
Aim. To perform comparative analysis of the diagnostic efficacy of sCD40L, PDGF-BB, VEGF-A and ST2 in recipients with cardiac rejection in different periods after transplantation. Materials and methods. The study included 144 cardiac recipients aged from 12 to 71 (mean age 44 Β± 14) years old, among those 112 were men. Venous blood plasma taken on the same day with endomyocardial biopsy was used for the study. The concentrations of soluble CD40 ligand (sCD40L), vascular endothelial growth factor (VEGF-A), platelet-derived growth factor (PDGF-BB) were measured using xMAP technology. The concentrations of ST2 were measured by ELISA. Results. Men had significantly higher levels of ST2 and VEGF-A compared to women (p = 0.03). No correlation was found between the levels of biomarkers (sCD40L, PDGF-BB, VEGF-A, ST2) and age, diagnosis before transplantation, presence of arterial hypertension and diabetes mellitus. Comparative analysis of the biomarkersβ levels didnβt show significant difference between patients with heart transplant rejection and without it in the first month and in the first year after transplantation. The ST2 level was significantly higher in patients with heart rejection (p = 0.01) in the long term period (1β5 years) after transplantation compared to patients without rejection. Relative risk of cardiac transplant rejection was significantly higher in patients with high (>22.8 ng/ml) ST2 level (RR = 2.59 Β± 0.33; Se β 35%, Sp β 93%). However, its combination with other biomarkers improved their diagnostic value. Relative risk for panel including ST2, VEGF-A and PDGF-BB 3.47 Β± 0.55, Se β 57%, Sp β 91%; relative risk for panel including ST2, sCD40L and PDGF-BB was 3.75 Β± 0.59, Se β 50%, Sp β 92%. The highest diagnostic efficacy for the heart transplant rejection was reached by a panel of biomarkers that included ST2 and PDGF-BB (RR = 5.0 Β± 0.56 [95% CI 1.68β14.92], Se β 63%, Sp β 94%). Conclusion. ST2 had the biggest diagnostic value for heart transplant rejection in the long term period after heart transplantation. Its usage as a part of complex tests with other biomarkers improves the sensitivity of noninvasive diagnosis of the cardiac rejection. The highest diagnostic significance for cardiac transplant rejection in the long term period was shown by a panel of ST2 and PDGF-BB.Π¦Π΅Π»Ρ. ΠΡΠΏΠΎΠ»Π½ΠΈΡΡ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ sCD40L, PDGF-BB, VEGF-A ΠΈ ST2 Π² ΡΠΎΡΡΠ°Π²Π΅ ΠΏΠ°Π½Π΅Π»Π΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΡΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ° Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 144 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ° ΡΠ΅ΡΠ΄ΡΠ° Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 12 Π΄ΠΎ 71 (44 Β± 14) Π³ΠΎΠ΄Π°, ΠΈΠ· Π½ΠΈΡ
112 ΠΌΡΠΆΡΠΈΠ½. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π²Π·ΡΡΠΎΠΉ Π² Π΄Π΅Π½Ρ ΡΠ½Π΄ΠΎΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠΏΡΠΈΠΈ. Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΠΉ ΡΠΎΡΠΌΡ Π»ΠΈΠ³Π°Π½Π΄Π° CD40 (sCD40L), ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ ΡΠΎΡΡΠ΄ΠΎΠ² (VEGF-A), ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² (PDGF-BB), ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ; ΡΡΠΎΠ²Π΅Π½Ρ ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° ST2 β Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΠΎΠ²Π΅Π½Ρ ST2 ΠΈ VEGF-A Π±ΡΠ» Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅ Ρ ΠΌΡΠΆΡΠΈΠ½, ΡΠ΅ΠΌ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ (p = 0,03). Π£ΡΠΎΠ²Π½ΠΈ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π½Π΅ Π·Π°Π²ΠΈΡΠ΅Π»ΠΈ ΠΎΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ°, Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° Π΄ΠΎ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ° (Π’Π‘), Π½Π°Π»ΠΈΡΠΈΡ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΠΈ, ΡΠ°Ρ
Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ° II ΡΠΈΠΏΠ°. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΡΠΎΠ²Π½Π΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π½Π΅ ΠΏΠΎΠΊΠ°Π·Π°Π» Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΉ ΡΠ°Π·Π½ΠΈΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΈ Π±Π΅Π· ΡΠ°ΠΊΠΎΠ²ΠΎΠ³ΠΎ Π² ΠΏΠ΅ΡΠ²ΡΠΉ ΠΌΠ΅ΡΡΡ ΠΈ Π² ΠΏΠ΅ΡΠ²ΡΠΉ Π³ΠΎΠ΄ ΠΏΠΎΡΠ»Π΅ Π’Π‘. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ST2 Π±ΡΠ»Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ΅ΡΠ΄ΡΠ°, ΡΠ΅ΠΌ Π±Π΅Π· ΡΠ°ΠΊΠΎΠ²ΠΎΠ³ΠΎ, Π² ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ (1β5 Π»Π΅Ρ) ΠΏΠΎΡΠ»Π΅ Π’Π‘ (p = 0,01). ΠΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ° Π² ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ Π’Π‘ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ ST2, ΠΏΡΠ΅Π²ΡΡΠ°ΡΡΠ΅ΠΉ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ (22,8 Π½Π³/ΠΌΠ»), Π² 2,6 ΡΠ°Π·Π° Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ ΡΠΈΡΠΎΠΊΠΈΠ½Π° Π½ΠΈΠΆΠ΅ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ (ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ β 35%, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ β 93%). ST2 Π² ΡΠΎΡΡΠ°Π²Π΅ ΠΏΠ°Π½Π΅Π»Π΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅Ρ ΠΈΡ
Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ: Π΄Π»Ρ ΠΏΠ°Π½Π΅Π»ΠΈ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ΅ΠΉ ST2, PDGF-BB ΠΈ VEGF-A, ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΊ ΡΠΎΡΡΠ°Π²Π»ΡΠ» 3,47 Β± 0,55 (ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ β 57%, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ β 91%); Π΄Π»Ρ ΠΏΠ°Π½Π΅Π»ΠΈ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ΅ΠΉ ST2, PDGF-BB ΠΈ sCD40L β 3,75 Β± 0,59 (ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ β 50%, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ β 92%) Π‘ΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ST2 ΠΈ PDGF-BB ΠΎΠ±Π»Π°Π΄Π°Π»ΠΎ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡ (RR = 5,00 Β± 0,56 [95% ΠΠ 1,68β14,92]; ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ β 63%, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ β 94%). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡ ΠΏΡΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ° Π² ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ ST2, ΠΈ Π΅Π³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π² ΡΠΎΡΡΠ°Π²Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ°ΠΌΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ»ΡΡΡΠΈΡΡ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ. ΠΠ°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡ Π² ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ Π’Π‘ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ ΠΏΠ°Π½Π΅Π»Ρ ΠΈΠ· Π΄Π²ΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ²: ST2 ΠΈ PDGF-BB
ΠΠΈΠΊΡΠΎΠ ΠΠ-27 ΠΈ -339 ΠΏΡΠΈ ΡΠΈΠ±ΡΠΎΠ·Π΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ°: Π°Π½Π°Π»ΠΈΠ· Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ
Myocardial fibrosis plays a key role in the pathogenesis of heart failure. A family of small non-coding signaling molecules, microRNAs (miRNAs), has been identified as promising profibrogenic biomarkers capable of signaling a possible risk of adverse events after heart transplantation.Objective: to identify and evaluate the diagnostic significance of miRNAs, as well as comprehensive miRNA-based tests in heart recipients with graft myocardial fibrosis.Materials and Methods. The study included 83 heart recipients aged 16 to 64 (48.4 Β± 13.1) years. The expression levels of five microRNAs (miR-27, -101, -142, -339, -424) in venous blood plasma were measured by quantitative real-time polymerase chain reaction; galectin-3 serum levels were determined by enzyme immunoassay.Results. Morphological signs of graft myocardial fibrosis were verified in 48 recipients. The miR-27 and miR-339 expression levels were significantly higher in heart recipients with myocardial fibrosis than in those without myocardial fibrosis (p = 0.018 and p = 0.043, respectively). Diagnostically significant threshold levels of miR-27 and miR-339 for detection of myocardial fibrosis in heart transplant recipients were determined (β4.33 and β5.24 units, respectively). The relative risk of detecting graft myocardial fibrosis in recipients with miR-27 expression value above the threshold level was RR = 1.5 Β± 0.157 [95% CI 1.104-2.039], p = 0.009; for miR-339, RR = 1.31 Β± 0.130 [95% CI 1.018-1.692], p = 0.036. When miR-27 expression levels and galectin-3 serum levels simultaneously exceeded their estimated thresholds, the risk of transplanted heart myocardial fibrosis increased to RR = 2.7 Β± 0.456 [95% CI 1.090-6.524], p = 0.032; when miR-339 and galectin-3 simultaneously exceeded threshold values, the risk was RR = 2.0 Β± 0.316 [95% CI 1.076-3.717], p = 0.028).Conclusion. The miR-27 and miR-339 expression levels are associated with the presence of fibrotic changes in the graft myocardium. The combination of molecular-genetic and proteomic biomarkers in one test improves the diagnostic characteristics of these expressions with respect to post-transplant complications in heart recipients.Π€ΠΈΠ±ΡΠΎΠ· ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈΠ³ΡΠ°Π΅Ρ ΠΊΠ»ΡΡΠ΅Π²ΡΡ ΡΠΎΠ»Ρ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ. Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ±ΡΠΎΠ³Π΅Π½Π½ΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², ΡΠΏΠΎΡΠΎΠ±Π½ΡΡ
ΡΠΈΠ³Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΌ ΡΠΈΡΠΊΠ΅ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΡΡ
ΡΠΎΠ±ΡΡΠΈΠΉ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ°, Π²ΡΠ΄Π΅Π»ΡΡΡ ΡΠ΅ΠΌΠ΅ΠΉΡΡΠ²ΠΎ ΠΌΠ°Π»ΡΡ
Π½Π΅ΠΊΠΎΠ΄ΠΈΡΡΡΡΠΈΡ
ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ» ΠΌΠΈΠΊΡΠΎΠ ΠΠ.Π¦Π΅Π»Ρ: Π²ΡΡΠ²ΠΈΡΡ ΠΈ ΠΎΡΠ΅Π½ΠΈΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΌΠΈΠΊΡΠΎΠ ΠΠ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² Π½Π° ΠΈΡ
ΠΎΡΠ½ΠΎΠ²Π΅ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 83 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ° ΡΠ΅ΡΠ΄ΡΠ° Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 16 Π΄ΠΎ 64 (48,4 Β± 13,1) Π»Π΅Ρ. Π ΠΏΠ»Π°Π·ΠΌΠ΅ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΡΡΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ (miR-27, -101, -142, -339, -424) ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ; ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Π²Π΅ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Ρ Ρ 48 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ². Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠΎΠ²Π½ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27 ΠΈ miR-339 Π·Π½Π°ΡΠΈΠΌΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ ΠΏΡΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ ΡΠ°ΠΊΠΎΠ²ΠΎΠ³ΠΎ (Ρ = 0,018 ΠΈ Ρ = 0,043 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΠ΅ Π²Π΅Π»ΠΈΡΠΈΠ½Ρ miR-27 ΠΈ miR-339 Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ° (β4,33 ΠΈ β5,24 ΠΎΡΠ½. Π΅Π΄. ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΊ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ Π²Π΅Π»ΠΈΡΠΈΠ½ΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27 Π²ΡΡΠ΅ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ ΡΠΎΡΡΠ°Π²ΠΈΠ» 1,5 Β± 0,157 [95% ΠΠ 1,104β2,039], Ρ = 0,009; Π΄Π»Ρ miR-339 β 1,31 Β± 0,130 [95% ΠΠ 1,018β1,692], Ρ = 0,036. ΠΡΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΡΡΠΎΠ²Π½Π΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 Π²ΡΡΠ΅ ΠΈΡ
ΡΠ°ΡΡΡΠΈΡΠ°Π½Π½ΡΡ
ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ° Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ Π΄ΠΎ 2,7 Β± 0,456 [95% ΠΠ 1,090β6,524], Ρ = 0,032; ΠΏΡΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΠΏΡΠ΅Π²ΡΡΠ΅Π½ΠΈΠΈ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ miR-339 ΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 ΡΠΈΡΠΊ ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ 2,0 Β± 0,316 [95% ΠΠ 1,076β3,717], Ρ = 0,028).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ miR-27 ΠΈ miR-339 ΡΠ²ΡΠ·Π°Π½Π° Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΡΠΈΠ±ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π² ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°. Π‘ΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΏΡΠΎΡΠ΅ΠΎΠΌΠ½ΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π² ΠΎΠ΄Π½ΠΎΠΌ ΡΠ΅ΡΡΠ΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΠΎΠ²ΡΡΠΈΡΡ Π΅Π³ΠΎ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°
ST2 IN REJECTION OF THE TRANSPLANTED HEART
This review summarizes the current literature devoted to the analysis of prognostic role of ST2 biomarker in rejection of the transplanted heart. ST2 is one of the most promising diagnostic markers of the development and severity of heart failure as well as the mortality risk in patients with cardiovascular diseases. ST2 is expressed in cardiomyocytes in response to a variety of pathological processes and mechanical damage to the heart, which allows diagnosing cardiovascular diseases before clinical manifestations. Presumably, measuring the level of ST2 in heart transplant may have diagnostic and prognostic value in the assessment of graft and risk of rejection. Currently, accumulated clinical data on the role of given biomarker in heart transplantation are not enough, and further research on the relation of ST2 levels with different clinical and laboratory parameters in heart recipients is necessary